Literature DB >> 6533103

Perfluoroctylbromide. Acute hemodynamic effects, in pigs, of intravenous administration compared with the standard ionic contrast media.

W W Peck, R F Mattrey, R A Slutsky, C B Higgins.   

Abstract

Perfluoroctylbromide (PFOB) is a relatively new noniodinated contrast media that, after intravenous administration, produces prolonged opacification of the blood pool and subsequently selectively enhances the liver and spleen on computed tomography. There has been concern regarding the hemodynamic effect of this agent but little actual knowledge exists in this regard. Accordingly, the acute transient hemodynamic effects of PFOB emulsion were evaluated in five pigs and compared with the standard ionic contrast agent meglumine sodium diatrizoate (Renografin-76). Left ventricular (LV) pressure, internal diameter, and wall thickness were monitored during the alternate intravenous administration of 930 mg/ml PFOB and 370 mg/ml R-76 at a rate of 20 mls/second for a total volume of 1 ml/kg body weight. Renografin-76 caused a significant decrease in LV pressure and dp/dt (rate of change of LV pressure), and an increase in LV end-systolic diameter and a decrease in LV end-diastolic wall thickness. PFOB caused no change in LV pressure and dimensions. Thus, rapid intravenous administration of PFOB does not induce significant acute alterations in left ventricular pressure, dp/dt, dimension, or wall thickness.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6533103     DOI: 10.1097/00004424-198403000-00010

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  2 in total

1.  Perfluorooctylbromide (PFOB) as a vitreous substitute in non-human primates.

Authors:  M D Conway; G A Peyman; M Karaçorlu; N Bhatt; K F Soike; L C Clark; R E Hoffmann
Journal:  Int Ophthalmol       Date:  1993-10       Impact factor: 2.031

2.  Recent Advances in 19Fluorine Magnetic Resonance Imaging with Perfluorocarbon Emulsions.

Authors:  Anne H Schmieder; Shelton D Caruthers; Jochen Keupp; Samuel A Wickline; Gregory M Lanza
Journal:  Engineering (Beijing)       Date:  2016-03-16       Impact factor: 7.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.